Literature DB >> 28182293

Standardizing the freeze-thaw preparation of growth factors from platelet lysate.

Gabriel Strandberg1, Felix Sellberg1, Pehr Sommar2, Martin Ronaghi1, Norbert Lubenow1, Folke Knutson1, David Berglund1.   

Abstract

BACKGROUND: Over the past decades, the focus on the regenerative properties of platelets (PLTs) has intensified and many PLT-derived growth factors are readily used in medical settings. A general lack of standardization in the preparation of these growth factors remains, however, and this study therefore examines the dynamics of growth factors throughout the freeze-thaw procedure. STUDY DESIGN AND METHODS: Plateletpheresis (PA) and PLT-poor plasma (PPP) samples were collected from 10 healthy donors. PA was lysed to produce PLT lysate (PL) for 1, 3, 5, 10, and 30 freeze-thaw cycles. The resulting growth factor and cytokine concentrations from PPP, PA, and PL of different cycles were analyzed and compared using enzyme-linked immunosorbent assay and multiplex bead assays.
RESULTS: PL produced by the freeze-thaw procedure resulted in approximately four- to 10-fold enrichment of transforming growth factor-β1, epidermal growth factor, PLT-derived growth factor (PDGF)-AB/BB, PLT factor-4, and fibroblast growth factor-2. The increase in concentrations plateaued at Cycles 3 and 5 and in some cases declined with further cycles. The concentrations of insulin-like growth factor-1, hepatocyte growth factor, vascular endothelial growth factor, and bone morphogenetic protein-2 in PL were essentially comparable to those in PPP.
CONCLUSION: Using the freeze-thaw method, optimal preparation of PL with regard to the concentration of growth factors was achieved at Cycles 3 to 5. Based on our findings, the clinical significance of using a greater number of cycles is likely limited.
© 2016 AABB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28182293     DOI: 10.1111/trf.13998

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  20 in total

1.  Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: from product development to clinical application.

Authors:  Dinara Samarkanova; Luciano Rodríguez; Joaquim Vives; Ruth Coll; Elisabet Tahull; Carmen Azqueta; Elena Valdivia; Margarita Codinach; Elisenda Farssac; Jesus Gaitan; Jose R Escudero; Sergio Querol
Journal:  Blood Transfus       Date:  2020-04-03       Impact factor: 3.443

Review 2.  Human platelet lysate - A potent (and overlooked) orthobiologic.

Authors:  Lucas da Fonseca; Gabriel Silva Santos; Stephany Cares Huber; Taís Mazzini Setti; Thiago Setti; José Fábio Lana
Journal:  J Clin Orthop Trauma       Date:  2021-07-28

3.  Comparison of the efficacy of cryopreserved human platelet lysate and refrigerated lyophilized human platelet lysate for wound healing.

Authors:  Sharon Claudia Notodihardjo; Naoki Morimoto; Natsuko Kakudo; Toshihito Mitsui; Tien Minh Le; Yasuhiko Tabata; Kenji Kusumoto
Journal:  Regen Ther       Date:  2018-11-20       Impact factor: 3.419

4.  Potential of a novel scaffold composed of human platelet lysate and fibrin for human corneal endothelial cells.

Authors:  Mohammad Amir Mishan; Sahar Balagholi; Tahereh Chamani; Sepehr Feizi; Zahra-Soheila Soheili; Mozhgan Rezaei Kanavi
Journal:  Cell Tissue Bank       Date:  2021-05-03       Impact factor: 1.522

5.  TGFβ activity released from platelet-rich fibrin adsorbs to titanium surface and collagen membranes.

Authors:  Francesca Di Summa; Zahra Kargarpour; Jila Nasirzade; Alexandra Stähli; Goran Mitulović; Tanja Panić-Janković; Veronika Koller; Cosima Kaltenbach; Heinz Müller; Layla Panahipour; Reinhard Gruber; Franz-Josef Strauss
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

6.  Positive impact of Platelet-rich plasma and Platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid.

Authors:  Daniel Steller; Nele Herbst; Ralph Pries; David Juhl; Samer G Hakim
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

7.  Cord blood and amniotic membrane extract eye drop preparations display immune-suppressive and regenerative properties.

Authors:  Dinara Samarkanova; Steven Cox; Diana Hernandez; Luciano Rodriguez; Maria Luisa Pérez; Alejandro Madrigal; Anna Vilarrodona; Sergio Querol; Ricardo P Casaroli-Marano
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

8.  Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine.

Authors:  Dinara Samarkanova; Steven Cox; Diana Hernandez; Luciano Rodriguez; Ricardo P Casaroli-Marano; Alejandro Madrigal; Sergio Querol
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

9.  Characteristics of Platelet Lysate Compared to Autologous and Allogeneic Serum Eye Drops.

Authors:  Jie Zhang; Daryl Crimmins; James M Faed; Peter Flanagan; Charles N J McGhee; Dipika V Patel
Journal:  Transl Vis Sci Technol       Date:  2020-03-24       Impact factor: 3.283

10.  Platelet lysates from aged donors promote human tenocyte proliferation and migration in a concentration-dependent manner.

Authors:  D R Berger; C J Centeno; N J Steinmetz
Journal:  Bone Joint Res       Date:  2019-02-02       Impact factor: 5.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.